Ignite Creation Date:
2024-05-05 @ 5:05 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00387751
Status:
COMPLETED
Last Update Posted:
2017-11-22
First Post:
2006-10-12
Brief Title:
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Phase II Pharmacokinetic PK Pharmacodynamic PD and Biological Correlative Study of the Efficacy and Safety of Dual Antiangiogenic Inhibition Using Bevacizumab and Sorafenib in Patients With Advanced Malignant Melanoma
Status:
COMPLETED
Status Verified Date:
2017-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase II trial is studying how well giving bevacizumab together with sorafenib works in treating patients with unresectable stage III or stage IV malignant melanoma Monoclonal antibodies such as bevacizumab can block tumor growth in different ways Some block the ability of tumor cells to grow and spread Others find tumor cells and help kill them or carry tumor-killing substances to them Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth Bevacizumab and sorafenib may also stop the growth of melanoma by blocking blood flow to the tumor Giving bevacizumab together with sorafenib may kill more tumor cells
Detailed Description:
PRIMARY OBJECTIVES
I Determine the clinical biologic activity of sorafenib tosylate and bevacizumab defined as the sum of complete response partial response and prolonged stable disease for 16 weeks in patients with unresectable stage III or stage IV malignant melanoma previously treated with at least 2 regimens of immunotherapy cytokines biologic therapy or vaccine therapy or in previously untreated patients who are not appropriate candidates to receive aldesleukin-based treatment
SECONDARY OBJECTIVES
I Evaluate the safety and tolerability of sorafenib tosylate and bevacizumab in these patients
II Evaluate the biologic activity of this regimen in terms of time to progression progression-free survival at 6 months and overall survival in these patients
III Describe significant pharmacokinetic interactions between bevacizumab and sorafenib tosylate
IV Characterize the pharmacodynamic relationships between the plasma concentration of sorafenib tosylate and bevacizumab and the effects of treatment on normal organ function and tumor tissue in these patients
V Identify predictive biomarkers of response to this regimen in these patients
VI Correlate changes in biological measurements with patient outcomes
OUTLINE This is an open-label multicenter study
Patients receive oral sorafenib tosylate on days 1-5 8-12 15-19 and 22-26 and bevacizumab IV over 30-90 minutes on days 1 and 15 Treatment repeats every 28 days in the absence of unacceptable toxicity or disease progression Blood samples and tumor biopsies are obtained periodically for pharmacokinetic and pharmacodynamic studies Samples are examined by liquid chromatography mass spectrometry immunohistochemistry gene expression analysis DNA mutation analysis and genomic analysis for biological markers
After completion of study treatment patients are followed for 4 weeks
I Determine the clinical biologic activity of sorafenib tosylate and bevacizumab defined as the sum of complete response partial response and prolonged stable disease for 16 weeks in patients with unresectable stage III or stage IV malignant melanoma previously treated with at least 2 regimens of immunotherapy cytokines biologic therapy or vaccine therapy or in previously untreated patients who are not appropriate candidates to receive aldesleukin-based treatment
SECONDARY OBJECTIVES
I Evaluate the safety and tolerability of sorafenib tosylate and bevacizumab in these patients
II Evaluate the biologic activity of this regimen in terms of time to progression progression-free survival at 6 months and overall survival in these patients
III Describe significant pharmacokinetic interactions between bevacizumab and sorafenib tosylate
IV Characterize the pharmacodynamic relationships between the plasma concentration of sorafenib tosylate and bevacizumab and the effects of treatment on normal organ function and tumor tissue in these patients
V Identify predictive biomarkers of response to this regimen in these patients
VI Correlate changes in biological measurements with patient outcomes
OUTLINE This is an open-label multicenter study
Patients receive oral sorafenib tosylate on days 1-5 8-12 15-19 and 22-26 and bevacizumab IV over 30-90 minutes on days 1 and 15 Treatment repeats every 28 days in the absence of unacceptable toxicity or disease progression Blood samples and tumor biopsies are obtained periodically for pharmacokinetic and pharmacodynamic studies Samples are examined by liquid chromatography mass spectrometry immunohistochemistry gene expression analysis DNA mutation analysis and genomic analysis for biological markers
After completion of study treatment patients are followed for 4 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U01CA069853 | NIH | CTEP | httpsreporternihgovquickSearchU01CA069853 |
| NCI-2009-00134 | REGISTRY | None | None |
| CDR0000502282 | None | None | None |
| 05-25 | None | None | None |
| 05-25 | OTHER | None | None |
| 7200 | OTHER | None | None |
| P30CA054174 | NIH | None | None |